Can you take Anagrelide with Plasminogen, human?
1 drug interaction and 4 additional warnings found for the following 2 drugs:
- anagrelide
- plasminogen, human
Drug interactions
Major drug interactions
Major:
anagrelide plasminogen, human
Applies to: anagrelide and plasminogen, human
Using plasminogen, human together with anagrelide may increase the risk of bleeding.
Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications.
You should seek immediate medical attention if you experience any unusual bleeding or bruising or have other signs and symptoms of bleeding such as:
- dizziness
- lightheadedness
- red or black, tarry stools
- coughing up or vomiting fresh or dried blood that looks like coffee grounds
- severe headache
- weakness
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Disease interactions
4 potential interactions Applies to: 4 conditions, including Liver Disease, Cardiovascular Conditions and Disorders, Renal Dysfunction, and Pulmonary Impairment.
Cardiovascular Conditions and Disorders
Major:
anagrelide
Anagrelide has a major potential interaction with Cardiovascular Conditions and Disorders.
The use of anagrelide may produce a positive inotropic effect, vasodilation, tachycardia, palpitations, and congestive heart failure. Therapy with anagrelide should be administered cautiously in patients with cardiac disease. A cardiovascular examination is recommended prior to beginning therapy with anagrelide.
Liver Disease
Major:
anagrelide
Anagrelide has a major potential interaction with Liver Disease.
Anagrelide undergoes extensive metabolism in the liver, with less than 1% recovered unchanged in the urine. Therapy with anagrelide should be administered cautiously in patients with liver disease (bilirubin, SGOT, or other liver measurements greater than 1.5 times normal) and only when the benefits outweigh the risks. Monitoring for signs of liver toxicity is recommended.
Pulmonary Impairment
Moderate:
anagrelide
Anagrelide has a moderate potential interaction with Pulmonary Impairment.
The use of anagrelide may cause interstitial lung diseases, including allergic alveolitis, eosinophilic pneumonia, and interstitial pneumonitis. The symptoms may present as progressive dyspnea with lung infiltrations. Close monitoring should be exercised when using this agent in patients with pulmonary dysfunction. It is recommended to discontinue anagrelide and evaluate the patient if symptoms of pulmonary toxicity occur.
Renal Dysfunction
Major:
anagrelide
Anagrelide has a major potential interaction with Renal Dysfunction.
The use of anagrelide has been rarely associated with renal failure most often in patients with serum creatinine values greater than 2.0. Therapy with anagrelide should be administered cautiously in patients with renal dysfunction. Monitoring for signs of renal toxicity is recommended in these patients.
Report options
More resources
anagrelide
A total of 443 drugs are known to interact with anagrelide.
- Anagrelide is in the drug class miscellaneous coagulation modifiers.
-
Anagrelide is used to treat the following conditions:
- Chronic Myelogenous Leukemia (off-label)
- Thrombocythemia
plasminogen, human
A total of 77 drugs are known to interact with plasminogen, human.
- Plasminogen, human is in the drug class miscellaneous uncategorized agents.
- Plasminogen, human is used to treat Hypoplasminogenemia.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.